Erythrasma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Irfan Dotani (talk | contribs) No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Erythrasma}} | {{Erythrasma}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{LRO}} | ||
==Overview== | |||
== | ==Natural History== | ||
==Complications== | |||
== | ==Prognosis== | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} |
Revision as of 17:46, 30 September 2016
Erythrasma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Erythrasma natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Erythrasma natural history, complications and prognosis |
FDA on Erythrasma natural history, complications and prognosis |
Erythrasma natural history, complications and prognosis in the news |
Blogs on Erythrasma natural history, complications and prognosis |
Risk calculators and risk factors for Erythrasma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Luke Rusowicz-Orazem, B.S.